[1]
|
王连唐, 程嘉骧, 黄世章.内分泌病理学[M].江西:江西科学技术出版社, 2006:253-296. |
[2]
|
中华医学会内分泌学分会肾上腺学组.嗜铬细胞瘤和副神经节瘤诊断治疗的专家共识[J].中华内分泌代谢杂志, 2016, 32:181-187. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhnfmdx201603002 |
[3]
|
Zuber SM, Kantorovich V, Pacak K. Hypertension in pheochromocytoma:characteristics and treatment[J]. Endocrinol Metab Clin North Am, 2011, 40:295-311. doi: 10.1016/j.ecl.2011.02.002 |
[4]
|
樊华, 李汉忠, 纪志刚, 等.嗜铬细胞瘤/副神经节瘤术中血压骤升的临床特征分析(附单中心219例报告)[J].中华泌尿外科杂志, 2019, 40:267-271. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhmnwk201904007 |
[5]
|
Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma:an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2014, 99:1915-1942. doi: 10.1210/jc.2014-1498 |
[6]
|
景红丽.生长抑素受体显像在嗜铬细胞瘤、副神经节瘤和肿瘤性骨软化症的临床应用研究[D].北京: 中国医学科学院北京协和医院, 2016. |
[7]
|
Janssen I, Blanchet EM, Adams K, et al. Superiority of[68Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma[J]. Clin Cancer Res, 2015, 21:3888-3895. doi: 10.1158/1078-0432.CCR-14-2751 |
[8]
|
邓建华, 李汉忠.嗜铬细胞瘤/副神经节瘤基因突变相关遗传综合征[J].协和医学杂志, 2015, 6:161-165. http://d.wanfangdata.com.cn/periodical/xhyx201503001 |
[9]
|
Neumann HPH, Young WF, Eng C. Pheochromocytoma and paraganglioma[J]. N Engl J Med, 2019, 381:552-565. doi: 10.1056/NEJMra1806651 |
[10]
|
Colao A, Grasso LFS, Giustina A, et al. Acromegaly[J]. Nat Rev Dis Primers, 2019, 5:20. doi: 10.1038/s41572-019-0071-6 |
[11]
|
Puglisi S, Terzolo M. Hypertension and acromegaly[J]. Endocrinol Metab Clin North Am, 2019, 48:779-793. doi: 10.1016/j.ecl.2019.08.008 |
[12]
|
Vilar L, Vilar CF, Lyra R, et al. Acromegaly:clinical features at diagnosis[J]. Pituitary, 2017, 20:22-32. doi: 10.1007/s11102-016-0772-8 |
[13]
|
Katznelson L, Laws ER, Melmed S, et al. Acromegaly:an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2014, 99:3933-3951. doi: 10.1210/jc.2014-2700 |
[14]
|
Zahr R, Fleseriu M. Updates in diagnosis and treatment of acromegaly[J]. Eur Endocrinol, 2018, 14:57-61. doi: 10.17925/EE.2018.14.2.57 |
[15]
|
Lloyd RV, Osamura RY, Kloppel G, et al. WHO classification of tumours of endocrine organs[M]. 4th ed. Lyon:International Agency for Research on Cancer, 2017:12-23. |
[16]
|
Trouillas J, Jaffrain-Rea ML, Vasiljevic A, et al. How to classify the pituitary neuroendocrine tumors (PitNET)s in 2020[J]. Cancers (Basel), 2020, 12. pii:E514.doi: 10.3390/cancers12020514. |
[17]
|
Stelmachowska-Banas M, Glogowski M, Vasiljevic A, et al. Ectopic acromegaly due to growth hormone-releasing hormone secretion from bronchial carcinoid causing somatotroph hyperplasia and partial pituitary insufficiency[J]. Pol Arch Intern Med, 2019, 129:208-210. |
[18]
|
中华医学会内分泌学分会.库欣综合征专家共识(2001年)[J].中华内分泌代谢杂志, 2011, 28:96-102. |
[19]
|
Barbot M, Ceccato F, Scaroni C. The pathophysiology and treatment of hypertension in patients with Cushing's syndrome[J]. Front Endocrinol (Lausanne), 2019, 10:321. doi: 10.3389/fendo.2019.00321 |
[20]
|
Araujo Castro M, Marazuela Azpiroz M. Two types of ectopic Cushing syndrome or a continuum? Review[J]. Pituitary, 2018, 21:535-544. doi: 10.1007/s11102-018-0894-2 |
[21]
|
Isidori AM, Sbardella E, Zatelli MC, et al. Conventional and nuclear medicine imaging in ectopic Cushing's syndrome:A systematic review[J]. J Clin Endocrinol Metab, 2015, 100:3231-3244. doi: 10.1210/JC.2015-1589 |
[22]
|
Kalla A, Krishnamoorthy P, Gopalakrishnan A, et al. Primary hyperparathyroidism predicts hypertension:Results from the National Inpatient Sample[J]. Int J Cardiol, 2017, 227:335-337. doi: 10.1016/j.ijcard.2016.11.080 |
[23]
|
Graff-Baker AN, Bridges LT, Chen Q, et al. Parathyroidectomy for patients with primary hyperparathyroidism and associations with hypertension[J]. JAMA Surg, 2019, 155:32-39. https://www.ncbi.nlm.nih.gov/pubmed/31596437 |
[24]
|
Fisher SB, Perrier ND. Primary hyperparathyroidism and hypertension[J]. Gland Surg, 2020, 9:142-149. doi: 10.21037/gs.2019.10.21 |